Compare Prospect Capital Corporation (PSEC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Sanofi SA — how do they compare? Prospect Capital Corporation trades at $2.14 (market cap $1.08B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 97.1× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (23.26%). Which is the better fit depends on your goals.
| PSEC | SNY | |
|---|---|---|
Market Cap | $1.08B | $104.85B |
Sector | Financials | Health |
52-Week High | $3.47 | $52.34 |
52-Week Low | $2.15 | $41.33 |
Dividend Yield | 23.26% | 5.53% |
Enterprise Value | — | $121.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prospect Capital Corporation (PSEC) trades at $2.15, down 4.44% on the day, reflecting persistent bearish technical signals. The company's fundamentals are challenged, with negative revenue of -$407M and a net income margin of -495.94% for 2025, though it has beaten EPS estimates for the last three consecutive quarters. Recent corporate actions include regular dividend payments, while news highlights portfolio activity and deep discounts to net asset value.
The outlook remains cautious due to weak profitability and a bearish analyst consensus. The primary opportunity lies in the stock's high yield and significant discount to book value, but risks include ongoing revenue volatility, declining net asset value, and skepticism about portfolio quality. Investors should weigh income potential against fundamental deterioration.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
